ArticleFrontiers in chemistry2026
A highly aqueous HPLC-PDA method for the assay of gabapentin and pregabalin: applications in pharmaceutical analysis, dissolution testing, and forensic screening.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gabapentinoids, particularly pregabalin (PGL) and gabapentin (GBP), are widely used for neurological and psychiatric conditions but are increasingly linked to misuse and forensic challenges. Their high polarity, zwitterionic nature, and lack of strong chromophores present significant analytical challenges, often requiring derivatisation or specialised chromatographic systems. This study aimed to develop and validate a green, derivatisation-free HPLC-PDA method for the simultaneous determination of PGL and GBP in pharmaceutical formulations and seized samples. Methods: Chromatographic separation was achieved on a Hypersil GOLD™ C18 column (150 × 3 mm, 3 µm). An isocratic, highly aqueous mobile phase of water:methanol (96:4, v/v) was used at a flow rate of 0.7 mL/min. Detection was performed at 205 nm. Method optimisation was supported by a 2 Results: The proposed method achieved effective separation without derivatisation, buffer systems, or specialised columns, while reducing organic solvent consumption compared to some reported methods. Calibration was linear over 5-60 μg/mL (r ≥ 0.9997). Accuracy ranged from 95%-103%. Intra- and inter-day precision (%RSD) values were below 5%. The limits of detection/quantification values were 0.31/1.03 μg/mL for PGL and 0.25/0.85 μg/mL for GBP. Dissolution studies confirmed rapid drug release meeting pharmacopoeial criteria. Application to seized samples revealed PGL content exceeding labelled values (106%-110%), while no peak corresponding to GBP was observed under the current HPLC-PDA conditions. Conclusion: The proposed method provides a simple, reliable, and environmentally favourable analytical approach for the simultaneous determination of gabapentinoids without complex sample preparation. Its successful application to pharmaceutical analysis, dissolution testing, and forensic samples highlights its suitability for routine laboratory use and regulatory monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.